Compounded tirzepatide vs Wegovy pill (oral semaglutide 25 mg)

Pros

• +Access to tirzepatide, the most effective molecule, at $199–$359/mo against Zepbound's $1,086 list.[1]
• +Vial dosing allows finer titration than branded pens.[1]

Cons

• −Not FDA approved — no review of safety, efficacy or manufacturing quality.[1]
• −Eli Lilly has active lawsuits against compounded tirzepatide sellers, including Henry Meds. A ruling against your provider ends your supply.[2]
• −The tirzepatide shortage that legally permitted mass compounding has been resolved, so the category now operates on contested legal ground.[2]
• −Zepbound vials through LillyDirect start at $299/mo — the branded gap is far smaller than it was, which weakens the only argument for compounding.[1]

Sources

1. [1] GLP-1 Telehealth Price Report 2026
2. [2] Mochi vs Henry Meds: two compounded providers under active litigation

Pros

• +13.6% mean weight loss on the label's own 64-week trial, intention-to-treat — the strongest result of any oral weight-loss drug approved to date.[5]
• +No injections, no needle disposal, no refrigeration.[4]
• +Self-pay from roughly $149/mo direct from Novo Nordisk, against $1,349 list for the injection.[3]
• +Same molecule as Wegovy injection, which has years of post-marketing safety data behind it.[4]

Cons

• −The $149 headline is the 1.5 mg starting month only. The 4 mg month is $199, and every month from 9 mg up — including the 25 mg dose you stay on — is $299, twice the advertised figure.[1]
• −Oral semaglutide has strict dosing conditions — taken on an empty stomach with a small sip of water and nothing else for 30 minutes. Adherence in the real world is worse than in trials, which is why this site uses the label's intention-to-treat 13.6%, counting everyone randomized, and not the 16.6% the paper reports for those who kept taking it.[5]
• −Telehealth programs add a membership on top of the drug — Ro and Hims both charge $149 a month on a monthly plan — while Novo sells the pill direct at $149 to $299 depending on dose.
• −Its 13.6% in the label's 64-week trial is below the 20.9% tirzepatide reached in SURMOUNT-1 on Zepbound's label; these were separate trials, not a head-to-head.[8]

Sources

1. [1] Wegovy cost and savings, NovoCare
2. [2] Wegovy Savings Offer terms, NovoCare
3. [3] FDA approves Novo Nordisk's Wegovy pill
4. [4] Novo Nordisk: Wegovy pill FDA approval announcement
5. [5] FDA approves oral semaglutide as first GLP-1 pill for weight loss
6. [6] FDA prescribing information for WEGOVY
7. [7] TrumpRx, the federal direct-purchase price site — $149 a month, tablet, read 6 September 2026
8. [8] FDA prescribing information for ZEPBOUND